140 related articles for article (PubMed ID: 38730723)
1. Sex Differences in Odds of Brain Metastasis and Outcomes by Brain Metastasis Status after Advanced Melanoma Diagnosis.
Cioffi G; Ascha MS; Waite KA; Dmukauskas M; Wang X; Royce TJ; Calip GS; Waxweiler T; Rusthoven CG; Kavanagh BD; Barnholtz-Sloan JS
Cancers (Basel); 2024 May; 16(9):. PubMed ID: 38730723
[TBL] [Abstract][Full Text] [Related]
2. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Meier F; Garzarolli M; Weichenthal M; Kähler K; Grimmelmann I; Gutzmer R; Utikal J; Terheyden P; Herbst R; Haferkamp S; Pfoehler C; Forschner A; Leiter U; Ziller F; Meiss F; Ulrich J; Kreuter A; Gebhardt C; Welzel J; Schilling B; Kaatz M; Scharfetter-Kochanek K; Dippel E; Nashan D; Sachse M; Weishaupt C; Löffler H; Gambichler T; Loquai C; Heinzerling L; Grabbe S; Debus D; Schley G; Hassel JC; Weyandt G; Trommer M; Lodde G; Placke JM; Zimmer L; Livingstone E; Becker JC; Horn S; Schadendorf D; Ugurel S
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028819
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
Moser JC; Bhatia S; Amin A; Pavlick AC; Betts KA; Du EX; Poretta T; Shelley K; Srinivasan S; Sakkal LA; Palaia J; Lobo M; Pe Benito M; Linton JA; Chen Y; Xu C; Yin L; Sundar M; Weber J
Cancer Immunol Immunother; 2024 May; 73(7):116. PubMed ID: 38713408
[TBL] [Abstract][Full Text] [Related]
4. Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1/L1 inhibitor therapy.
Hepp Z; Shah SN; Liang SY; Tan K; Balakrishna S
Future Oncol; 2021 Nov; 17(32):4343-4353. PubMed ID: 34350778
[TBL] [Abstract][Full Text] [Related]
5. Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016.
Brastianos HC; Nguyen P; Sahgal A; Eisenhauer EA; Baetz T; Hanna TP
JAMA Netw Open; 2020 Jul; 3(7):e208204. PubMed ID: 32663310
[TBL] [Abstract][Full Text] [Related]
6. Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
Jahanzeb M; Lin HM; Pan X; Yin Y; Wu Y; Nordstrom B; Socinski MA
Oncologist; 2020 Oct; 25(10):867-877. PubMed ID: 32490560
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis.
Cowey CL; Scherrer E; Boyd M; Aguilar KM; Beeks A; Krepler C
J Immunother; 2021 Jul-Aug 01; 44(6):224-233. PubMed ID: 33734142
[TBL] [Abstract][Full Text] [Related]
9. Real-world multiple myeloma front-line treatment and outcomes by transplant in the United States.
Richter J; Pan D; Salinardi T; Rice MS
EJHaem; 2023 Nov; 4(4):984-994. PubMed ID: 38024614
[TBL] [Abstract][Full Text] [Related]
10. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
van Zeijl MCT; Haanen JBAG; Wouters MWJM; de Wreede LC; Jochems A; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM; van den Eertwegh AJM
J Immunother; 2020 Oct; 43(8):256-264. PubMed ID: 32804914
[TBL] [Abstract][Full Text] [Related]
11. Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records.
Polito L; Shim J; Hurvitz SA; Dang CT; Knott A; Du Toit Y; Restuccia E; Sanglier T; Swain SM
JCO Oncol Pract; 2023 Jul; 19(7):435-445. PubMed ID: 37167571
[TBL] [Abstract][Full Text] [Related]
12. Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer.
Whitaker KD; Wang X; Ascha M; Showalter TN; Lewin HG; Calip GS; Goldstein LJ
Breast Cancer Res Treat; 2022 Nov; 196(1):163-173. PubMed ID: 36028783
[TBL] [Abstract][Full Text] [Related]
13. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract][Full Text] [Related]
14. First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma.
Wang X; Haaland B; Hu-Lieskovan S; Colman H; Holmen SL
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1419. PubMed ID: 34137219
[TBL] [Abstract][Full Text] [Related]
15. Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types.
Torres AZ; Nussbaum NC; Parrinello CM; Bourla AB; Bowser BE; Wagner S; Tabano DC; George D; Miksad RA
Adv Ther; 2022 Jun; 39(6):2831-2849. PubMed ID: 35430670
[TBL] [Abstract][Full Text] [Related]
16. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
[TBL] [Abstract][Full Text] [Related]
17.
Petracci FE; Villarreal-Garza C; Argañaraz F; Abuin GG; Peñaloza J; Flores MA; Piazzoni L; Riggi C; Fabiano L; González L; Cieplinski B; Rivero S; Korbenfeld E; Mandó P
Ecancermedicalscience; 2023; 17():1634. PubMed ID: 38414929
[TBL] [Abstract][Full Text] [Related]
18. Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry.
van Zeijl MCT; de Wreede LC; van den Eertwegh AJM; Wouters MWJM; Jochems A; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven JJM; Haanen JBAG
Eur J Cancer; 2021 Feb; 144():242-251. PubMed ID: 33373869
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
[TBL] [Abstract][Full Text] [Related]
20. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
Lamba N; Ott PA; Iorgulescu JB
JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
